Immuneering Corp (NASDAQ: IMRX) is a clinical-stage oncology company that discovers and develops small molecule drug candidates using a proprietary computational biology platform. The company generates no product revenue as of the fiscal year ended December 31, 2025, funding operations through equity issuances, including a September 2025 private placement to Aventis (a wholly owned subsidiary of Sanofi) that raised $23.4 million in net proceeds. Immuneering's lead asset, envometinib, is a MEK inhibitor in Phase 1 clinical trials, with interim monotherapy data as of December 23, 2024 showing up to 77% inhibition of phosphorylated ERK across dose levels of 40 mg to 160 mg twice daily in seventeen evaluable patients. The platform centers on Disease Cancelling Technology (DCT) for target identification and humanized 3D tumor models for translational planning. Operating cash outflow was $45.3 million for the year ended December 31, 2025, compared to $55.0 million in 2024. The company has never commercialized a product and carries no sales or distribution infrastructure.

Revenue model

No product revenue. Immuneering funds operations through equity financing. In September 2025, the company raised $23.4 million in net proceeds via a private placement of 2,708,559 common shares at $9.23 per share to Aventis (Sanofi subsidiary). Interest income is earned on cash, cash equivalents, and marketable securities holdings.

Products and services

Envometinib: a small molecule MEK inhibitor in Phase 1 clinical trials targeting MAPK pathway-driven cancers, including KRAS-mutant colorectal cancer. Atebimetinib: a second clinical-stage product candidate referenced in strategic transaction provisions. Disease Cancelling Technology (DCT): a proprietary computational platform using transcriptomic data for target identification and drug optimization. Humanized 3D tumor growth models: used for translational and preclinical drug evaluation.

Customers and end markets

No commercial customers as of FY2025. End markets are oncology patients with MAPK pathway-driven cancers, including KRAS-mutant colorectal cancer. Physicians prescribing oncology therapeutics represent the eventual prescriber base. The company has no sales force or marketing organization as of the 10-K filing date of March 6, 2026.

Value-chain role

Preclinical and clinical-stage drug discoverer and developer. Immuneering occupies the research, target identification, and early clinical development stages of the pharmaceutical value chain. It has no manufacturing, commercial sales, or distribution capabilities and would need to build or partner for commercialization.

Geographic exposure

Incorporated and headquartered in the United States. No geographic revenue breakdown disclosed given absence of product revenue.

Source: SEC 10-K, filed 2026-03-06

Industry: Pharmaceutical Preparations Peers: Annexon Inc Arbutus Biopharma Corp AVEO PHARMACEUTICALS, INC. Tango Therapeutics Inc Bioatla Inc CONCERT PHARMACEUTICALS, INC. GreenLight Biosciences Holdings, PBC Sutro Biopharma Inc Generation Bio Co.